NEWARK, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in upcoming investor conferences, including the 2018 Cantor Global Healthcare Conference, the LEERINK Partners Roundtable Series: Rare Disease & Oncology, and the ROTH Battle of the NASH Thrones Investor Conference.
|2018 Cantor Global Healthcare Conference|
|Date:||Monday, October 1|
|Time:||8:55am Eastern Time|
|Location:||Intercontinental Barclay New York Hotel|
|LEERINK Partners Roundtable Series: Rare Disease & Oncology|
|Date:||Tuesday, October 2|
|Time:||8:30am Eastern Time|
|Location:||Lotte New York Palace Hotel|
|ROTH Battle of the NASH Thrones Investor Conference|
|Date:||Wednesday, October 17|
|Time:||Panel discussions and 1-on-1 meetings|
|Location:||Park Hyatt New York Hotel|
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist, currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with non-alcoholic steatohepatitis (NASH).
For additional information about CymaBay visit www.cymabay.com.
LifeSci Advisors, LLC